Baddour LM, Weimer MB, Wurcel AG, McElhinney DB, Marks LR, Fanucchi LC, et al. Management of Infective Endocarditis in People Who Inject Drugs: A Scientific Statement From the American Heart Association. Circulation 2022;146(14):e187-e201. https://www.ncbi.nlm.nih.gov/pubmed/36043414
Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr., Tleyjeh IM, Rybak MJ, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015;132(15):1435-86. https://www.ncbi.nlm.nih.gov/pubmed/26373316
Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989;2(8671):1071-3. https://www.ncbi.nlm.nih.gov/pubmed/2572799
Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015;36(44):3075-128. https://www.ncbi.nlm.nih.gov/pubmed/26320109
Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996;101(1):68-76. https://www.ncbi.nlm.nih.gov/pubmed/8686718
Kussmann M, Karer M, Obermueller M, Schmidt K, Barousch W, Moser D, et al. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Emerg Microbes Infect 2018;7(1):202. https://www.ncbi.nlm.nih.gov/pubmed/30514923
Le Bot A, Lecomte R, Gazeau P, Benezit F, Arvieux C, Ansart S, et al. Is Rifampin Use Associated With Better Outcome in Staphylococcal Prosthetic Valve Endocarditis? A Multicenter Retrospective Study. Clin Infect Dis 2021;72(9):e249-e55. https://www.ncbi.nlm.nih.gov/pubmed/32706879
Lee JYH, Monk IR, Goncalves da Silva A, Seemann T, Chua KYL, Kearns A, et al. Global spread of three multidrug-resistant lineages of Staphylococcus epidermidis. Nat Microbiol 2018;3(10):1175-85. https://www.ncbi.nlm.nih.gov/pubmed/30177740
Marks LR, Liang SY, Muthulingam D, Schwarz ES, Liss DB, Munigala S, et al. Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections. Clin Infect Dis 2020;71(10):e650-e6. https://www.ncbi.nlm.nih.gov/pubmed/32239136
Miller WR, Seas C, Carvajal LP, Diaz L, Echeverri AM, Ferro C, et al. The Cefazolin Inoculum Effect Is Associated With Increased Mortality in Methicillin-Susceptible Staphylococcus aureus Bacteremia. Open Forum Infect Dis 2018;5(6):ofy123. https://www.ncbi.nlm.nih.gov/pubmed/29977970
Munoz P, De la Villa S, Martinez-Selles M, Goenaga MA, Reviejo-Jaka K, Revillas FAL, et al. Linezolid for infective endocarditis: A structured approach based on a national database experience. Medicine (Baltimore) 2021;100(51):e27597. https://www.ncbi.nlm.nih.gov/pubmed/34941026
Nannini EC, Stryjewski ME, Singh KV, Bourgogne A, Rude TH, Corey GR, et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother 2009;53(8):3437-41. https://www.ncbi.nlm.nih.gov/pubmed/19487449
Shmueli H, Thomas F, Flint N, Setia G, Janjic A, Siegel RJ. Right-Sided Infective Endocarditis 2020: Challenges and Updates in Diagnosis and Treatment. J Am Heart Assoc 2020;9(15):e017293. https://www.ncbi.nlm.nih.gov/pubmed/32700630
Spellberg B, Chambers HF, Musher DM, Walsh TL, Bayer AS. Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis: A Narrative Review. JAMA Intern Med 2020;180(5):769-77. https://www.ncbi.nlm.nih.gov/pubmed/32227127
Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna. Clin Infect Dis 2018;67(5):795-8. https://www.ncbi.nlm.nih.gov/pubmed/29659732
Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG, Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015;28(3):603-61. https://www.ncbi.nlm.nih.gov/pubmed/26016486
